Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?

作     者：Lisa Derosa Laurence Zitvogel Lisa Derosa;Laurence Zitvogel

作者机构：Gustave Roussy Comprehensive Cancer InstituteClinicobiomeVillejuifFrance Faculty of MedicineUniversite Paris SaclayLe Kremlin-BicetreFrance INSERM U1015VillejuifFrance Equipe labellisee par la Ligue contre le cancerVillejuifFrance Center of Clinical Investigations in Biotherapies of Cancer(CICBT)BIOTHERISVillejuifFrance Suzhou Institute for Systems MedicineChinese Academy of Medical SciencesSuzhouChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2021年第6卷第6期

页      面：1630-1631页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：al. melanoma clinical 

摘      要：In two recent articles,Baruch et al.1 and Davar et al.2 bring up the first proof-of-concept that fecal microbiota transplantation(FMT)transfer clinical benefit in metastatic melanoma patients primarily resistant to immune checkpoint blockade(ICB).FMT shifted the microbiota of recipients toward a donor-type taxonomic composition associated with immune activation,anti-inflammatory tonus,and changes in the host metabolism.